couldn’t that just mean that the test is most well suited to stopping disease in individuals that are considered low risk which would be a lot of type 2 diabetics? I don’t see how those two statements from NICE and MSAC are so different? The aim is to stop end stage renal failure in people who would normally be considered low risk and aren’t captured until it’s too late? Thoughts?
couldn’t that just mean that the test is most well suited to...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.010(2.67%) |
Mkt cap ! $59.68M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 37.5¢ | 36.0¢ | $41.74K | 113.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 17814 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 95239 | 2 |
View Market Depth
| Last trade - 15.57pm 18/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |